# EDGAR Filing Document

**Accession Number:** 0001643301
**File Stem:** 0001477932-23-000318
**Filing Date:** 2023-1
**Character Count:** 15656
**Document Hash:** e10bc125e3fdd17363a09645fa45d135
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-000318.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001477932-23-000318

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20221014

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avenir Wellness Solutions, Inc.
- **CENTRAL INDEX KEY:** 0001643301
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 371765151
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55908
- **FILM NUMBER:** 23530914

**BUSINESS ADDRESS:**
- **STREET 1:** 5805 SEPULVEDA BLVD., SUITE 801
- **CITY:** SHERMAN OAKS
- **STATE:** CA
- **ZIP:** 91411
- **BUSINESS PHONE:** 424-273-8675

**MAIL ADDRESS:**
- **STREET 1:** 5805 SEPULVEDA BLVD., SUITE 801
- **CITY:** SHERMAN OAKS
- **STATE:** CA
- **ZIP:** 91411

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cure Pharmaceutical Holding Corp.
- **DATE OF NAME CHANGE:** 20161209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Makkanotti Group Corp.
- **DATE OF NAME CHANGE:** 20150526

?xml version="1.0" encoding="utf-8"?curr_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

Date of Report (Date of earliest event reported): **October 14, 2022**

---

| |
|:---|
| **AVENIR WELLNESS SOLUTIONS, INC.** |
| (Exact name of registrant as specified in its charter) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-55908** | **37-1765151** |
| (State or other jurisdiction  | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **5805 Sepulveda Blvd., Suite 801**<br>**Sherman Oaks, California** | **91411** |
| (Address of principal executive offices) | (Zip Code) |

---

 **<u>(424) 273-8675</u>**

(Registrant's telephone number, including area code)

**<u>CURE Pharmaceutical Holding Corp.</u>**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

By a written consent dated as of September 20, 2022, the Board of Directors of CURE Pharmaceutical Holding Corp. (the "Company") approved an amendment to its certificate of incorporation to change its name to "Avenir Wellness Solutions, Inc." (the "Amendment"). On October 14, 2022, the Company filed the Amendment with the Secretary of State of the State of Delaware. The Company has submitted a request to the Financial Industry Regulatory Authority, Inc. to obtain a new trading symbol for its common stock that aligns with its new name. A new symbol has not been issued as of the date of this Current Report on Form 8-K.

**Item 7.01 Regulation FD Disclosure.** 

On January 17, 2023, the Company issued a press release announcing the filing of the Amendment and the pending approval of its new trading symbol as described in detail in Item 5.03 above. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein solely for purposes of this Item 7.01 disclosure. Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be "filed" under the Securities Exchange Act of 1934, as amended.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [3.1](curr_ex31.htm) | [Certificate of Amendment of Certificate of Incorporation](curr_ex31.htm) |
| [99.1](curr_ex991.htm) | [Press Release dated as of January 17, 2023](curr_ex991.htm) |
| 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |

---

2<br>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AVENIR WELLNESS SOLUTIONS, INC.** | **AVENIR WELLNESS SOLUTIONS, INC.** |
| Date: January 17, 2023 | *By:* | */s/ Nancy Duitch* |
|  | Name:  | Nancy Duitch |
|  | Title: | Chief Executive Officer |

---

3<br>

## Exhibit 3.1

**EXHIBIT 3.1**

![](curr_ex31img1.jpg)

## Exhibit 99.1

**EXHIBIT 99.1**

**CURE Pharmaceutical Unveils Exciting New Brand Identity with Name Change to Avenir Wellness Solutions, Inc.**

***New branding reflects Company's commitment to the future of wellness***

SHERMAN OAKS, CA--(ACCESSWIRE)--January 17, 2023 – CURE Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE" or the "Company"), a proprietary broad platform and wellness technology company, today announced that it has changed its name to "Avenir Wellness Solutions, Inc." ("Avenir Wellness") which will be the name for the company as a corporate entity. The name change is the result of the Company's recent sale of certain intellectual property. More importantly, however, the name change reflects the renewed focus of the Company with its incubator strategy and continuing efforts to create and commercialize wellness technologies with quality products and brands in the wellness and beauty space. The Company has also released a new corporate logo and launched a new website at: ***www.avenirwellness.com***.

The legal name "CURE Pharmaceutical Holding Corp." has already been officially changed with the state of Delaware where the Company is incorporated and will be fully changed to "Avenir Wellness Solutions, Inc." upon satisfying all applicable regulatory requirements. Concurrently, the Company's OTCQB ticker symbol "CURR" will also be changed. Once approved, the new ticker symbol and effective date of the changes will be publicly announced. No action is needed from current stockholders. The Company's common stock will continue to be traded on OTCQB Markets and the CUSIP number will not be changing.

This rebranding is part of the Company's shareholder value initiatives and ongoing commitment to delivering innovative and highly desired wellness technologies to the marketplace. The Company's long-term growth strategy is to increase revenue with high margins, use its incubator strategy to grow the patent and product portfolio as well as monetize the intellectual property ("IP") patent technology through strategic partnerships. These initiatives, along with the Company's relationships with Nicole Kidman and other major social media influencers, is expected to help propel its health and beauty products to become a household name, consistent with its strategy to become a genuine house of recognizable and respected quality brands.

Value Proposition of Avenir Wellness Solutions:

1. Technology – Provide innovative wellness solutions to improve ordinary dietary supplement and beauty product delivery systems that currently exist in the market.

2. Strong Patent Portfolio – Monetize the 15 current and pending patents through licensing and royalty arrangements while developing new proprietary patents.

3. Established Network – Utilize its network of industry leading sales, marketing and product development experts to transform the Company into a trusted and reliable brand that stands for quality and commitment to its customers.

4. Growth Plans – Execute multiple strategies that will be used to expand patent portfolio and product offerings, improve cash flow, and ensure profitability, including strategic transactions, potential future mergers and acquisitions, as well as joint venture partnerships.

5. Management Expertise – Fully exploit the many decades of management experience in the health, wellness, and beauty sectors and innovative product development with unique intellectual property.

"Providing cutting edge products, proprietary delivery systems, and impactful marketing strategies to an enormous health and wellness industry that is desperate for new innovations and solutions is the key for us to becoming a House of Quality Brands. Rebranding the Company and delivering on our value proposition is very exciting, and it will ultimately increase shareholder value," stated CEO Nancy Duitch.

Ms. Duitch continued, "The beauty and wellness markets are growing at rapid rates. The global wellness sector, despite the pandemic, saw exponential growth in 2021 with a market size of $1.5 trillion, according to McKinsey. There is a strong overall and growing demand for supplements and nutraceuticals, a $587.3 billion market, according to the 2021 Grandview report. The beauty and personal care industry is a $534 billion market now and is set to grow 5.87% year over year according to Terakeet's 2021 Beauty Industry Report. This significant market growth combined with our innovative proprietary delivery technology we are continuing to expand led us to enhance our future focus and commitment of our Company to these high margin/high growth areas. We are **<u>not</u>** in the business of selling just vitamins or topicals. Rather, we are putting technology with real intellectual property behind our wellness products to create a better way of delivering active ingredients to the consumer, with the goal of being more effective. We believe our proprietary technology differentiates us from our competition, producing quality high-margin products with improved safety, efficacy, and consumer experience."

For more information, please visit ***www.avenirwellness.com*** & ***www.seralabshealth.com***.

**About Avenir Wellness Solutions, Inc. (f/k/a Cure Pharmaceutical Holding Corp.)** 

Avenir Wellness® (OTCQB: CURR) is a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on 15 current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that will be part of its incubator strategy in order to monetize its IP. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide.

**About The Sera Labs, Inc.**

The Sera Labs, Inc. ("Sera Labs"), a wholly-owned subsidiary of Avenir Wellness, is a trusted leader in the wellness and beauty sectors utilizing cutting edge technology and high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale and is strategically positioned to grow its beauty and wellness products into household brands. Sera Labs products are sold Direct to Consumer with a subscribe and save option, as well as in major national drug, grocery chains, and mass retailers. For more information visit ***www.seralabshealth.com*** and follow Sera Labs on Facebook and Instagram at @seratopical, as well as on Twitter at @sera_labs.

**Forward Looking Statement**

*This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.*

*Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.*

*Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.*

Contacts:

Investor Relations

Hanover International Inc.

T: (760) 564-7400

E: investor@avenirwellness.com

Public Relations

Autumn Communications

Rachel Moskowitz

T: (202) 276-7881

E: rmoskowitz@autumncommunications.com